Pyrazole and Pyrazoline-Based EGFR TK Inhibitors: A Review Study Emphasizing Structure-Activity Relationship (SAR)

Area of Science:

• Oncology
• Medicinal Chemistry

Background:

• Epidermal Growth Factor Receptor (EGFR) abnormalities drive uncontrolled cell growth and carcinoma development.
• Cancer cells develop resistance to treatments like tyrosine kinase inhibitors (TKIs) due to EGFR-associated gene mutations.
• Fourth-generation TKIs targeting the C797S mutation are current standards for EGFR-mutated cancers.

Purpose of the Study:

• To review pyrazole and pyrazoline derivatives as potential anti-cancer agents.
• To analyze structure-activity relationships (SAR) of these compounds against EGFR tyrosine kinase inhibitors.
• To guide optimization of novel antiproliferative agents.

Main Methods:

• Literature review of anti-cancer agents developed over the last 15 years.
• Focus on pyrazole and pyrazoline derivatives.
• Analysis of compound activity and SAR.

Main Results:

• Identified 31 potential anti-cancer compounds.
• Detailed activity characteristics and SAR for pyrazole and pyrazoline derivatives.
• Highlighted compounds as EGFR tyrosine kinase inhibitors.

Conclusions:

• Pyrazole and pyrazoline scaffolds show promise as EGFR inhibitors.
• SAR analysis is crucial for optimizing antiproliferative efficacy.
• Further research can lead to improved cancer therapies overcoming resistance.